Tag Archive for: Series A financing

Obstructive sleep apnea (OSA) specialist Mosanna Therapeutics AG has secured US$80m in a Series A financing to fund clinical testing through Phase II of its nasal OSA spray MOS118.

German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.

Mablink Bioscience has baged €31m in a Series A round led by Sofinnova Partners and Mérieux Equity Partners to speed up its pipeline of ADCs.